Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial
scientific article published on 23 August 2017
Author/s
author: Athanasios Dimopoulos, Albert Oriol, Roman Hajek, Thierry Facon, Ruben Niesvizky, Hartmut Goldschmidt, Philippe Moreau, Heinz Ludwig, Robert Z Orlowski, Katja Weisel, Vania Hungria, Wee Joo Chng, Leonard Minuk, Anita Zahlten-Kumeli
Work details
Copyright status
Copyright status information is not available for this work. The copyright status depends on the jurisdiction, the author's date of death and the date the work was created or published.
To learn more about copyright terms in different countries, visit the countries and terms page.